TB-500 appears in community discussions about muscle, tendon and joint recovery. Its name is associated with thymosin beta-4, a protein involved in cell movement and tissue repair, but marketed fragments and full-length thymosin beta-4 are different molecules.
Research focus: Soft-tissue recovery and mobility.
Choose a compound to open its research, documentation and calculator.
No FDA-approved drug product for this catalog material. Compounding eligibility and approval are separate questions.
Official source ↗PeptIQ’s reported value has not been matched here to a primary human PK study for the exact molecule and route. Treat it as a reference estimate, not an established dosing interval.
Half-life describes concentration falling by half. It does not set a dosing interval, a storage period or a drug-test detection window.
Kinetics source ↗PeptIQ lists bacteriostatic water for repeated-vial workflows. That preference is not a compatibility study for a particular formulation; the actual product or pharmacy instructions determine the liquid.
Bacteriostatic water contains a preservative; plain sterile water does not. Preservative presence does not by itself establish compatibility or a mixed medicine’s usable period.
Preparation source ↗Confirm the sequence and formulation. Full-length thymosin beta-4 studies cannot establish the effects of a product labeled TB-500.
Check that a source concerns the same molecule, formulation, route and population. A study of cells, animals or a different product cannot confirm the contents of a vial.
Identity and formulation review; findings for full-length thymosin beta-4 need to be read separately.
Other names you may encounter: TB500.
Learn to read a study →Each entry keeps one schedule’s amount, frequency and cycle together. Community references, individual reports, clinical trials and prescription products describe different kinds of use. A missing duration or break stays marked as not reported.
Amounts describe mass in mg or mcg. Syringe units describe volume and depend on concentration. A cycle break is different from days off within a week.
Choose an option to explore its amounts, timing and cycle.
| When | Amount & frequency |
|---|---|
| Weeks 1–6 · loading | 2–2.5 mg twice weekly (4–5 mg/week) |
| Weeks 7–12 · maintenance | 2–2.5 mg once weekly |
Weeks 1–6 use two injections per week; weeks 7–12 use one. A shorter 4–6-week loading period is also discussed in community guides.
| When | Amount & frequency |
|---|---|
| First 4–6 weeks · loading | 2–2.5 mg twice weekly (4–5 mg/week) |
| Remaining weeks · maintenance | 2 mg once weekly |
A separate cycle from the 12-week example above. Some descriptions include a later taper to 2 mg every other week.
| When | Amount & frequency |
|---|---|
| First couple of weeks | 500 mcg twice weekly |
| After about 15 days | 1 mg twice weekly (2 mg/week) |
BPC-157 was used alongside TB-500 in separate vials. These amounts refer to the TB-500 component of an individual account.
A peptide name and vial mass cannot determine a compatible diluent, powder displacement, storage temperature or discard date. Follow the exact product’s instructions and your pharmacist’s directions.
The injection guide concerns clinician-prescribed subcutaneous medicines; it does not establish that a research-labeled material can be injected.
Start with the formulation: dry powder, prepared solution, pen, tablet and topical product can have different instructions.
General health habits and consistent observations help you assess changes. They are not evidence that a peptide’s effects will be amplified.
A diagnosis, progressive rehabilitation and an appropriate return to activity help put pain and function changes in context.
NIAMS · injury treatment and recovery ↗Use a regular sleep/wake schedule and note changes in sleep quality alongside symptoms or training.
CDC · sleep habits ↗What to record: Record pain, movement, training load and rehabilitation together. Feeling less pain and demonstrating structural healing are different outcomes.
Check dates are editorial references, not a medical review certificate. Labels and evidence can change; consult the linked current document.
Opening values and worked examples illustrate arithmetic; they are not preparation instructions or recommended amounts. Selecting a compound labels the calculation and does not supply a dose or powder-volume correction.
Enter the documented vial mass, preparation information and target amount to see how mass and volume connect.
20 mg in an assumed final 1 mL gives 20 mg/mL. An entered 1 mg corresponds to 0.05 mL, or 5 U-100 units, with 20 theoretical portions before losses.
Estimate · assumes 1 mL added = total volume
1,000 mcg
Theoretical · before losses
0.2 mL
After 5 full doses
Illustration only · calculated value, without rounding
Saved calculations stay on this device.
Concentration = mass ÷ final volume
5 mg ÷ 1 mL = 5 mg/mLVolume = target mass ÷ concentration
1 mg ÷ 5 mg/mL = 0.2 mLU-100 markings = volume × 100
0.2 mL × 100 = 20 unitsComplete portions = floor(vial mass ÷ amount per portion).
Displayed numbers are rounded for readability; the calculation uses unrounded values.
Already have the concentration? Find the matching mL and U-100 syringe reading.
Need the concentration first? Use the Reconstitution tab.
5units
0.05 mL · 0.25 mg
0.25 mg ÷ 5 mg/mL = 0.05 mLU-100 units = mL × 100Example inputs are editable. The reading is calculated without rounding to a physical graduation.
Convert mass or liquid volume. U-100 markings always refer to a 100-units-per-mL scale.
1,000mcg
For mass → syringe volume, switch to Dosage and enter a concentration.